DNA methylation is a key epigenetic modifier involved in tumor formation, invasion,
and metastasis. The development of breast cancer is a complex process, and many studies have
now confirmed the involvement of DNA methylation in breast cancer. Moreover, the number of
genes identified as aberrantly methylated in breast cancer is rapidly increasing, and the accumulation
of epigenetic alterations becomes a chronic factor in the development of breast cancer. The
combined effects of external environmental factors and the internal tumor microenvironment promote
epigenetic alterations that drive tumorigenesis. This article focuses on the relevance of DNA
methylation to breast cancer, describing the role of detecting DNA methylation in the early diagnosis,
prediction, progression, metastasis, treatment, and prognosis of breast cancer, as well as recent
advances. The reversibility of DNA methylation is utilized to target specific methylation aberrant
promoters as well as related enzymes, from early prevention to late targeted therapy, to understand
the journey of DNA methylation in breast cancer with a more comprehensive perspective.
Meanwhile, methylation inhibitors in combination with other therapies have a wide range of
prospects, providing hope to drug-resistant breast cancer patients.